



# From Curiosity to Discovery

International Research & Development Press Conference

## Speaker Biography



**Michel Pairet, M.D.**  
**Corporate Senior Vice President, Research, Boehringer Ingelheim**

Michel Pairet joined Boehringer-Ingelheim in 1992 where he was successively leading Pharmacology, Pulmonary Disease research, the German Research Site, in charge in charge of therapeutic areas Thromboembolic, Pulmonary, CNS and Metabolic Diseases, and Head of Corporate Research.

With his team, Michel Pairet has generated a competitive development pipeline covering all preclinical and clinical phases, he was also involved in the profiling of a number of marketed compounds, including meloxicam (Mobic<sup>®</sup>), a preferential COX-2 inhibitor for the treatment of Osteoarthritis and Rheumatoid Arthritis, and tiotropium (Spiriva<sup>®</sup>), an inhaled anticholinergic for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and dabigatran (Pradaxa<sup>®</sup>), a first-in-class direct thrombin inhibitor.

Michel Pairet obtained doctorates in both Veterinary Medicine and Physiology and Pharmacology in Toulouse, France.